Form 4: Bain Capital Increases Stake in Solid Biosciences Through Public Offering

Bain Capital Life Sciences entities increased their investment in Solid Biosciences through a recent underwritten public offering, acquiring common stock and pre-funded warrants.

Summary

• Bain Capital Life Sciences Investors, LLC and affiliated entities have reported changes in their beneficial ownership of Solid Biosciences Inc. (SLDB) common stock.
• On February 19, 2025, BCLS II Investco, LP purchased 1,000,000 shares of SLDB common stock at $4.03 per share and pre-funded warrants to purchase 6,444,170 shares at $4.029 per share in an underwritten public offering.
• Following the transaction, Bain Capital Life Sciences entities beneficially own a total of 5,034,582 shares of common stock and pre-funded warrants for 6,444,170 shares.
• The pre-funded warrants are subject to a 9.99% ownership limitation and do not expire.

Sentiment

Score: 7

Explanation: The document indicates a positive sentiment due to Bain Capital's increased investment in Solid Biosciences, suggesting confidence in the company's prospects. However, it's a standard transaction, so the sentiment isn't extremely high.

Positives

• Bain Capital's increased investment signals confidence in Solid Biosciences.
• The pre-funded warrants provide Solid Biosciences with additional capital flexibility.

Risks

• The pre-funded warrants have a 9.99% ownership limitation, which could restrict the potential upside for Bain Capital.
• The value of the investment is subject to the market performance of Solid Biosciences' stock.

Future Outlook

The document does not contain specific forward-looking statements regarding Solid Biosciences' future performance.

Industry Context

This investment reflects ongoing activity in the biotechnology sector, where institutional investors like Bain Capital Life Sciences frequently participate in public offerings to support companies like Solid Biosciences.

Comparison to Industry Standards

• Bain Capital Life Sciences' investment in Solid Biosciences is similar to other investments made by venture capital and private equity firms in the biotech industry.
• Comparable companies that have received similar investments include those focused on gene therapy and rare diseases.
• The size of the investment is within the typical range for underwritten public offerings in the biotech sector.

Stakeholder Impact

• Shareholders may view Bain Capital's increased investment positively.
• The capital raise could enable Solid Biosciences to further its research and development efforts.

Key Dates

Keywords

Solid Biosciences, Bain Capital, common stock, pre-funded warrants, beneficial ownership, investment, SLDB, public offering